Loading...
Market
Will AUCATZYL® (obe-cel) achieve $100 million in sales by end of Q1 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Autolus Therapeutics' quarterly financial reports
Story
Autolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
